Head to Head Review: Nyxoah (NASDAQ:NYXH) & IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ:IDXX) and Nyxoah (NASDAQ:NYXH) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares IDEXX Laboratories and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	N/A	N/A	N/A
Nyxoah	N/A	N/A	N/A

Risk and Volatility

IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for IDEXX Laboratories and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0	6	9	0	2.60
Nyxoah	1	1	2	0	2.25

IDEXX Laboratories currently has a consensus target price of $727.69, indicating a potential upside of 29.66%. Nyxoah has a consensus target price of $3.55, indicating a potential upside of 289.95%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than IDEXX Laboratories.

Institutional & Insider Ownership

87.8% of IDEXX Laboratories shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares IDEXX Laboratories and Nyxoah”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.55 billion	9.71	$1.12 billion	$14.22	39.47
Nyxoah	$21.66 million	1.63	-$97.68 million	($2.52)	-0.36

IDEXX Laboratories has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

IDEXX Laboratories beats Nyxoah on 9 of the 11 factors compared between the two stocks.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.